BioStem Technologies (OTCMKTS:BSEM) Stock Price Down 3.5% – Time to Sell?

BioStem Technologies, Inc. (OTCMKTS:BSEM)’s share price fell 3.5% during trading on Friday . The company traded as low as $3.72 and last traded at $3.8960. 32,995 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 71,423 shares. The stock had previously closed at $4.0365.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BSEM. Zacks Research upgraded shares of BioStem Technologies to a “hold” rating in a report on Wednesday, March 18th. HC Wainwright began coverage on shares of BioStem Technologies in a report on Wednesday, May 6th. They issued a “buy” rating and a $9.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $9.00.

BioStem Technologies Price Performance

The firm has a market capitalization of $69.15 million, a P/E ratio of -3.50 and a beta of 0.03. The stock’s fifty day simple moving average is $4.50 and its 200 day simple moving average is $4.81.

BioStem Technologies (OTCMKTS:BSEM) last announced its earnings results on Thursday, May 14th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.24). The business had revenue of $6.14 million for the quarter, compared to analyst estimates of $5.70 million. As a group, sell-side analysts forecast that BioStem Technologies, Inc. will post -1.95 EPS for the current fiscal year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.